Overview |
bs-70327r-100ul |
AIFM1 (Ser-116), Phosphospecific Antibody |
WB |
The antibody was cross adsorbed to unphosphorylated AIFM1 (Ser-116) peptide before affinity purification using phospho-AIFM1 (Ser-116) peptide. This antibody antibody detects a triplet at 66, 62, and 57 kDa* protein on SDS-PAGE immunoblots of human Jurkat cells treated with calyculin A. |
Human |
Specifications |
Unconjugated |
Rabbit |
Phospho-AIFM1 (Ser-116) synthetic peptide (coupled to carrier) corresponding to amino acids surrounding Ser-116 in human AIFM1. |
Ser-116 |
Polyclonal |
IgG |
Antigen Affinity purification |
PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
Target |
O95831 |
PDCD8, AIF1, Apoptosis inducing factor 1, mitochondrial; Program cell death protein 8; striatal AIF |
Apoptosis-inducing factor (AIFM1, AIF, PDCD8) is a ubiquitously expressed flavoprotein that plays a critical role in caspase-independent apoptosis. AIFM1 is expressed as a 66 kDa precursor protein before being N-terminally cleaved to 62 kDa and localized to the mitochondrial intermembrane space. In response to apoptotic stimuli, AIFM1 is released from the mitochondrial intermembrane as a 57 kDa fragment that can translocate to the nucleus. Treatment of isolated nuclei with recombinant AIFM1 leads to early apoptotic events, such as chromatin condensation and large-scale DNA fragmentation. Studies of AIFM1 knockout mice have shown that the apoptotic activity of AIFM1 is cell type and stimuli-dependent. AIFM1 has been implicated in oxeiptosis, a non-inflammatory, caspase independent cell death pathway caused by oxidative stress. During oxeiptosis, increased reactive oxygen species cause the release of the phosphatase PGAM5 from KEAP1 leading to dephosphorylation of AIFM1 (Ser-116) and subsequent cell death. Thus, AIFM1 phosphorylation status at Ser-116 may be an important marker for cell death involving oxeiptosis. |
Application Dilution |
WB |
1:300-5000 |